Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement

References

• LjungbergBCampbellSCChoiHYThe epidemiology of renal cell carcinomaEur Urol201160461562121741761
   PubMed Web of Science ®Google Scholar
• ReuterVEThe pathology of renal epithelial neoplasmsSemin Oncol200633553454317045082
   PubMed Web of Science ®Google Scholar
• SimardEPWardEMSiegelRJemalACancers with increasing incidence trends in the United States: 1999 through 2008CA Cancer J Clin201262211812822281605
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIErvikMGLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11. 20132015 Available from: http://globocan.iarc.frAccessed March 24, 2015
   Google Scholar
• BazarbashiSAl OthmanKAl OtaibiMSaudi Oncology Society clinical management guidelines for renal cell carcinomaUrol Ann20113SupplS3S521673849
   PubMedGoogle Scholar
• LagunaMPAlgabaFCadedduJClinical Research Office of the Endourological Society Renal Mass StudyCurrent patterns of presentation and treatment of renal masses: a clinical research office of the endourological society prospective studyJ Endourol201428786187024555480
   PubMed Web of Science ®Google Scholar
• LjungbergBBensalahKBexAEAU Guidelines on Renal Cell Carcinoma2014 Available from: http://uroweb.org/guideline/renal-cell-carcinoma/Accessed March 22, 2015
   Google Scholar
• El DibRToumaNJKapoorACryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studiesBJU Int2012110451051622304329
   PubMed Web of Science ®Google Scholar
• JoniauSTsivianMGonteroPRadiofrequency ablation for the treatment of small renal masses: safety and oncologic efficacyMinerva Urol Nefrol201163322723621993321
   PubMed Web of Science ®Google Scholar
• VolpeACadedduJACestariAContemporary management of small renal massesEur Urol201160350151521664040
   PubMed Web of Science ®Google Scholar
• MacLennanSImamuraMLapitanMCUCAN Systematic Review Reference GroupEAU Renal Cancer Guideline PanelSystematic review of oncological outcomes following surgical management of localised renal cancerEur Urol201261597299322405593
   PubMed Web of Science ®Google Scholar
• Van PoppelHDa PozzoLAlbrechtWA prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaEur Urol201159454355221186077
   PubMed Web of Science ®Google Scholar
• KarakiewiczPIBrigantiAChunFKMulti-institutional validation of a new renal cancer-specific survival nomogramJ Clin Oncol200725111316132217416852
   PubMed Web of Science ®Google Scholar
• KattanMWReuterVMotzerRJKatzJRussoPA postoperative prognostic nomogram for renal cell carcinomaJ Urol20011661636711435824
   PubMed Web of Science ®Google Scholar
• LamJSShvartsOLeppertJTPantuckAJFiglinRABelldegrunASPostoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification systemJ Urol20051742466472 discussion 472; quiz 80116006866
   PubMed Web of Science ®Google Scholar
• LeibovichBCBluteMLChevilleJCPrediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trialsCancer20039771663167112655523
   PubMed Web of Science ®Google Scholar
• MickischGHGarinAvan PoppelHde PrijckLSylvesterRRadical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialLancet2001358928696697011583750
   PubMed Web of Science ®Google Scholar
• FlaniganRCSalmonSEBlumensteinBANephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancerN Engl J Med2001345231655165911759643
   PubMed Web of Science ®Google Scholar
• AbernMRScosyrevETsivianMMessingEMPolascikTJDudekAZSurvival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy eraAnticancer Res20143452405241124778051
   PubMed Web of Science ®Google Scholar
• HengDYWellsJCRiniBICytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumEur Urol201466470471024931622
   PubMed Web of Science ®Google Scholar
• BexAPowlesTSelecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and whenExpert Rev Anticancer Ther201212678779722716495
   PubMed Web of Science ®Google Scholar
• KenneyPAWoodCGIntegration of surgery and systemic therapy for renal cell carcinomaUrol Clin North Am2012392211231vii22487764
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol19991782530254010561319
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMExternal validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyLancet Oncol201314214114823312463
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCSchmidingerMESMO Guidelines Working GroupRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii49iii5625210086
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol201028132137214320368558
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPAVOREN Trial InvestigatorsBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNégrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalJ Clin Oncol201028132144215020368553
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• SternbergCNHawkinsREWagstaffJA randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateEur J Cancer20134961287129623321547
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTECellaDPazopanib versus sunitinib in metastatic renal-cell carcinomaN Engl J Med2013369872273123964934
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTEMcCannLDeenKChoueiriTKOverall survival in renal-cell carcinoma with pazopanib versus sunitinibN Engl J Med2014370181769177024785224
   PubMed Web of Science ®Google Scholar
• MotzerRJMcCannLDeenKPazopanib versus sunitinib in renal cancerN Engl J Med201336920197024224635
   PubMedGoogle Scholar
• WittesJPazopanib versus sunitinib in renal cancerN Engl J Med201336920196924224637
   PubMedGoogle Scholar
• CasperJSchumann-BinarschSKohneCHPazopanib versus sunitinib in renal cancerN Engl J Med201336920196924224638
   PubMedGoogle Scholar
• IacovelliRVerzoniEDe BraudFProcopioGFirst line treatment of metastatic renal cell carcinoma: two standards with different toxicity profileCancer Biol Ther2014151192124253418
   PubMed Web of Science ®Google Scholar
• SunMTrinhQDPerrottePKarakiewiczPIWords of wisdom: re: pazopanib versus sunitinib in metastatic renal-cell carcinomaEur Urol20146551014101524646500
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Kidney Cancer Version 3.20152014 Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdfAccessed March 22, 2015
   Google Scholar
• HudesGCarducciMTomczakPGlobal ARCC TrialTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSRECORD-1 Study GroupEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSRECORD-1 Study GroupPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factorsCancer2010116184256426520549832
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• ZustovichFLombardiGNicolettoOPastorelliDSecond-line therapy for refractory renal-cell carcinomaCrit Rev Oncol Hematol201283111212221944739
   PubMed Web of Science ®Google Scholar
• BellmuntJDutcherJTargeted therapies and the treatment of non-clear cell renal cell carcinomaAnn Oncol20132471730174023625974
   PubMed Web of Science ®Google Scholar
• AltALBoorjianSALohseCMCostelloBALeibovichBCBluteMLSurvival after complete surgical resection of multiple metastases from renal cell carcinomaCancer2011117132873288221692048
   PubMed Web of Science ®Google Scholar
• DutcherJPMouradWFEnnisRDIntegrating innovative therapeutic strategies into the management of renal cell carcinomaOncology (Williston Park)201226652653022870536
   PubMed Web of Science ®Google Scholar
• HansonPWElaimyALLamoreauxWTA concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastasesWorld J Surg Oncol20121017622931379
   PubMed Web of Science ®Google Scholar
• RanckMCGoldenDWCorbinKSStereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinomaAm J Clin Oncol201336658959522868242
   PubMed Web of Science ®Google Scholar
• BexAGoreMMuldersPSternbergCNRecent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized careBJU Int201211091289130022624610
   PubMed Web of Science ®Google Scholar
• LjungbergBThe role of metastasectomy in renal cell carcinoma in the era of targeted therapyCurr Urol Rep2013141192523212738
   PubMed Web of Science ®Google Scholar
• KollmannsbergerCBjarnasonGBurnettPSunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicitiesOncologist201116554355321490127
   PubMed Web of Science ®Google Scholar
• KollmannsbergerCSoulieresDWongRScaleraAGaspoRBjarnasonGSunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effectsCan Urol Assoc J200712 SupplS41S5418542784
   PubMed Web of Science ®Google Scholar
• SchmidingerMArnoldDSzczylikCWagstaffJRavaudAOptimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practiceCancer Invest201028885686420504222
   PubMed Web of Science ®Google Scholar
• SchmidingerMLarkinJRavaudAExperience with sunitinib in the treatment of metastatic renal cell carcinomaTher Adv Urol20124525326523024706
   PubMedGoogle Scholar
• RiniBICohenDPLuDRHypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibJ Natl Cancer Inst2011103976377321527770
   PubMed Web of Science ®Google Scholar
• RautiolaJDonskovFPeltolaKJoensuuHBonoPSunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patientsBJU Int Epub9232014
   Google Scholar
• SchmidingerMVoglUMBojicMHypothyroidism in patients with renal cell carcinoma: blessing or curse?Cancer2011117353454420845482
   PubMed Web of Science ®Google Scholar
• DonskovFMichaelsonMPuzanovIComparative assessment of sunitinib-associated adverse events (AEs) as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC)Presented at: European Society for Medical OncologySeptember 28 to October 2, 2012Vienna, Austria
   Google Scholar
• JanowitzTWelshSJZakiKMuldersPEisenTAdjuvant therapy in renal cell carcinoma-past, present, and futureSemin Oncol201340448249123972712
   PubMed Web of Science ®Google Scholar
• SciarraACattarinoSSalcicciaSThe emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?Crit Rev Oncol Hematol201281215116221388825
   PubMed Web of Science ®Google Scholar
• AminCWallenEPruthiRSCalvoBFGodleyPARathmellWKPreoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomyUrology20087286486818684493
   PubMed Web of Science ®Google Scholar
• RiniBIGarciaJElsonPThe effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgeryJ Urol201218751548155422425095
   PubMed Web of Science ®Google Scholar
• KaramJADevineCEUrbauerDLPhase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinomaEur Urol201466587488024560330
   PubMed Web of Science ®Google Scholar
• ClarkeNWManagement of the spectrum of hormone refractory prostate cancerEur Urol2006503428438 discussion 438–42916797118
   PubMed Web of Science ®Google Scholar
• DevittBPhilipJMcLachlanSATeam dynamics, decision making, and attitudes toward multidisciplinary cancer meetings: health professionals’ perspectivesJ Oncol Pract201066e17e2021358945
   PubMedGoogle Scholar
• EllisPMThe importance of multidisciplinary team management of patients with non-small-cell lung cancerCurr Oncol201219Suppl 1S7S1522787414
   PubMed Web of Science ®Google Scholar
• KessonEMAllardiceGMGeorgeWDBurnsHJMorrisonDSEffects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 womenBMJ2012344e271822539013
   PubMed Web of Science ®Google Scholar